App-Quantinova.ai

An ongoing safety registry to identify rare and severe complications in children with paediatric-onset IBD

M A Aardoom - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

The efficacy of colesevelam to treat bile acid malabsorption in Crohn's disease: data from TOPPIC trial

A Devarakonda - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Cholestyramine

Steroid treatment for longer than 2 weeks leading to admission predicts higher colectomy rates in children with acute severe ulcerative colitis

C Tzivinikos - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

6-mercaptopurine

Extraintestinal manifestations and quality of life in patients with ulcerative colitis: 1-year data from ICONIC

S Ghosh - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Inflammatory bowel disease

N/A

The use of tacrolimus in patients with ulcerative colitis resistant to standard medical therapy

T Shafi - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Tacrolimus

Systemic and tissue modulation of IL-23 pathway biomarkers in a Phase 2 study of risankizumab in patients with Crohn’s disease

A Salas - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Risankizumab

Transanal minimal invasive proctectomy (TaMIP) for perineal Crohn’s disease; a multi-centre prospective cohort study

P Chandrasinghe - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Rescue infliximab for acute severe colitis: a single-centre experience

J Orpen-Palmer - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Infliximab

Characterisation of patients with delayed response to ustekinumab for Crohn’s disease

B E Sands - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

Ustekinumab for refractory paediatric Crohn’s disease: experience from two UK tertiary referral centres

R Rao - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

Ustekinumab: early experience and medium-term outcomes from a UK multi-centre real-world cohort

R Gadhok - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Ustekinumab

Comparative Analysis of Monotherapy and Combination Biological Therapy for Crohn’s disease and ulcerative colitis: Results from a Multi-Country Study in Europe

P Robinson - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Barriers to prescribing anti-TNF therapy in inflammatory bowel disease (IBD) across newly industrialised emerging market countries: an analysis of the ‘EXPLORE’ study

B D Ye - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

The impact of early disease control with vedolizumab on surgery rates among patients with Crohn’s disease: a post-hoc analysis of the GEMINI trials

P Dulai - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Entyvio

Switching from originator infliximab to CT-P13: single-centre experience from the UK

A P Bhandare - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Infliximab

Identification and management of psychological distress after stoma surgery: a qualitative study of patients and healthcare professionals

K Polidano - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Evaluation of dietetic services and the impact of diet on disease activity for patients with inflammatory bowel disease at Imperial College Healthcare NHS Trust

H Sandhar - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Safety and efficacy of ferric carboxymaltose (FCM) for the treatment of iron deficiency anaemia in paediatric patients affected by inflammatory bowel disease (pIBD)

L Cococcioni - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Ferric carboxymaltose

Thiopurine adverse events in patients with inflammatory bowel disease in the UK: inflammatory bowel disease BioResource cohort

Y Y Hong - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

6-mercaptopurine

Could an escalation of therapy or intervention (ETI) calculator be used to triage appointments for patients with ulcerative colitis?

A Walsh - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Filters

45280 Abstracts